LEO Pharma to Showcase New Data Highlighting the Burden and Unmet Needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen

Key Takeaways:

• LEO Pharma is recognized worldwide for its medical dermatology expertise.
• ESCD 2026 will be held in Copenhagen, Denmark, on LEO Pharma’s home ground.
• The company is unveiling findings on the burden and symptom severity of chronic hand eczema.
• Unmet needs remain a key concern, pointing to the urgency for better solutions.
• The publication date highlights the timeliness of this new research.

LEO Pharma Sets the Stage

LEO Pharma A/S, known for its innovative leadership in medical dermatology, has announced its plans to share new research at the upcoming European Society of Contact Dermatitis (ESCD) Congress 2026. This event marks an important moment as the company continues to reinforce its global commitment to improving patient care.

Copenhagen Hosts Key Dermatology Congress

Set to take place in Copenhagen, Denmark—LEO Pharma’s home base—the ESCD Congress 2026 is expected to draw dermatology professionals from around the world. The congress provides a platform for experts to exchange ideas on critical skin concerns, offering international attendees a glimpse into the latest findings and treatments.

Highlighting Chronic Hand Eczema’s Burden

During the congress, LEO Pharma will emphasize the pressing challenges involved in addressing chronic hand eczema (CHE). The new data underscores both the burden and severity of the disease, which can significantly impact patients’ daily lives. By bringing CHE to the forefront, LEO Pharma aims to drive conversations that may spur further research into improved therapies for those affected.

Looking Ahead for Solutions

In addition to presenting groundbreaking data, LEO Pharma’s program at ESCD 2026 signals an ongoing effort to tackle the unmet needs of CHE patients. By drawing attention to these needs, the company fosters collaboration among healthcare professionals, researchers, and patient advocates. Through such initiatives, LEO Pharma hopes to open doors to potential advancements and ensure that patients living with chronic hand eczema receive the care and support they deserve.